Exenatide
The first GLP-1 receptor agonist, a synthetic copy of a peptide found in Gila monster venom. It lowers blood sugar and, in the weekly form, proved safe for the heart without proving it protects it; its trials in Parkinson's disease ended in a negative phase 3.
Exenatide was approved as Byetta, a twice-daily injection for type 2 diabetes, on April 28, 2005, and later as the weekly Bydureon and Bydureon BCise. Its label describes a 39-amino-acid peptide first identified in the lizard Heloderma suspectum, with a half-life of 2.4 hours. Weekly semaglutide lowered glucose and weight more in a head-to-head trial.
What is it?
Exenatide is the synthetic form of exendin-4, a peptide the Byetta label describes as originally identified in the lizard Heloderma suspectum, the Gila monster. It activates the receptor for GLP-1, the gut hormone that raises insulin when blood sugar is high, lowers glucagon and slows the stomach, but unlike GLP-1 it survives in the blood long enough to be a drug. Byetta, approved on April 28, 2005, was the first medicine of its class: 5 µg injected under the skin within an hour before the two main meals, rising to 10 µg after a month. Its half-life is 2.4 hours.
The weekly versions came next. Bydureon, exenatide in slow-release microspheres, was approved on January 27, 2012, and the Bydureon BCise autoinjector on October 20, 2017; Drugs@FDA now lists both as discontinued, as it does Byetta's original application, although a Byetta label is still posted on DailyMed and a generic exenatide injection from Amneal was approved on November 19, 2024. The weekly form was tested in EXSCEL, a trial of 14,752 people with type 2 diabetes followed for a median of 3.2 years: major cardiovascular events occurred in 11.4% on exenatide against 12.2% on placebo, which showed it was safe for the heart but not that it protects it (hazard ratio 0.91, not significant for superiority).
Newer drugs have overtaken it. In a 56-week head-to-head trial, weekly semaglutide 1.0 mg lowered HbA1c by 1.5 points against 0.9 with weekly exenatide 2.0 mg and weight by 5.6 kg against 1.9 kg; injection-site reactions were far more common with exenatide (22.0% against 1.2%), gastrointestinal effects less so. In young people aged 10 to 17 with type 2 diabetes, weekly exenatide lowered HbA1c by 0.85 points more than placebo over 24 weeks. An implantable exenatide pump (ITCA 650) met its cardiovascular safety margin in 4,156 patients, with events in 4.6% against 3.8% on placebo.
Exenatide has also been tested in brain diseases. A 2017 trial in 62 people with moderate Parkinson's disease found off-medication motor scores 3.5 points better than placebo after 48 weeks of weekly injections and a 12-week washout, which led to a phase 3 trial. That trial, in 194 people for 96 weeks, found no difference: scores worsened by 5.7 points on exenatide and 4.5 on placebo. A small Alzheimer's pilot, stopped early, found no clinical or cognitive effect. In 15 women with idiopathic intracranial hypertension it lowered measured brain pressure within hours, and in people with obesity taking olanzapine it prevented the drug's weight gain (-0.5 kg against +2.6 kg on placebo).
Its safety profile is the class's. The label warns of acute pancreatitis, severe gastrointestinal reactions, kidney injury from dehydration and low blood sugar when combined with insulin or sulfonylureas, and it is not recommended in severe kidney impairment (creatinine clearance below 30 mL/min). A 2008 case report describes pancreatitis from the eighth day of Byetta that resolved when it was stopped. In EXSCEL, rates of pancreatitis, pancreatic cancer and medullary thyroid carcinoma did not differ from placebo. Exenatide is not on WADA's Prohibited List.
Mechanism of Action
Exenatide binds the GLP-1 receptor, the same receptor as semaglutide and liraglutide. It was the first of them, and its label gives it a half-life of 2.4 hours.
Glucose-dependent insulin
It raises insulin when glucose is high and lowers glucagon, which is why it rarely causes low blood sugar alone but can with insulin or sulfonylureas (label).
Slower stomach
Byetta is injected within an hour before the two main meals, when its effect on the rise in glucose after eating matters most (label dosing).
Twice daily or weekly
Byetta's 2.4-hour half-life means two injections a day; the weekly forms put the same peptide in slow-release microspheres.
Beyond glucose
Trials tested whether it protects the heart (no significant benefit) and the brain (a positive phase 2 in Parkinson's, then a negative phase 3).
Published Research
PubMed returns about 5,300 records for exenatide. Our evidence set holds 52 papers; 43 name it in their titles and have an abstract, and 11 are carded below, all studies in people: the cardiovascular outcome trials, the head-to-head with semaglutide, the youth trial and the brain trials. Exenatide is an approved drug, so its evidence is deep; the cards pick the trials that answered the biggest questions.
EXSCEL: weekly exenatide and the heart, 14,752 people
People with type 2 diabetes, 73% with previous cardiovascular disease, received weekly exenatide 2 mg or placebo for a median 3.2 years. Major cardiovascular events occurred in 11.4% against 12.2% (hazard ratio 0.91, 95% CI 0.83 to 1.00): non-inferior for safety but not superior. Pancreatitis, pancreatic cancer and medullary thyroid carcinoma did not differ.
SUSTAIN 3: weekly semaglutide vs exenatide ER
Over 56 weeks, semaglutide 1.0 mg lowered HbA1c by 1.5 points against 0.9 with exenatide ER 2.0 mg and weight by 5.6 kg against 1.9 kg; 67% against 40% reached HbA1c below 7%. Gastrointestinal events were more common with semaglutide (41.8% vs 33.3%), injection-site reactions with exenatide (22.0% vs 1.2%).
ITCA 650: an implanted exenatide pump, 4,156 people
In a pre-approval cardiovascular safety trial, the primary outcome occurred in 4.6% on continuous subcutaneous exenatide infusion and 3.8% on placebo over a median 16 months (hazard ratio 1.21), within the pre-set non-inferiority margin; serious adverse events were similar.
Weekly exenatide in youth with type 2 diabetes, 83 people
Participants aged 10 to 17 received exenatide 2 mg weekly or placebo. At 24 weeks HbA1c had fallen 0.36 points on exenatide and risen 0.49 on placebo, a difference of 0.85 points (p = 0.012); differences in fasting glucose, blood pressure and weight favoured exenatide but were not significant.
Parkinson's disease phase 2, 62 people
People with moderate Parkinson's disease received weekly exenatide 2 mg or placebo for 48 weeks, then a 12-week washout. Off-medication motor scores improved by 1.0 point on exenatide and worsened by 2.1 on placebo, an adjusted difference of 3.5 points (p = 0.032). Injection-site reactions and gut symptoms were common.
Parkinson's disease phase 3, 194 people
Across six UK hospitals, weekly exenatide 2 mg or placebo for 96 weeks: off-medication motor scores worsened by 5.7 points on exenatide and 4.5 on placebo (p = 0.47). It was safe and well tolerated (serious adverse events 9% vs 11%), but there was no evidence that it slowed the disease.
Alzheimer's disease pilot, stopped early
A phase 2 trial in early Alzheimer's disease confirmed by spinal-fluid markers was terminated early by its sponsor; 18 people completed it. Exenatide was safe, with more nausea and less appetite, but produced no differences in clinical, cognitive, MRI or fluid biomarker measures apart from lower amyloid-beta 42 in neuronal vesicles. The study was underpowered.
Idiopathic intracranial hypertension, 16 women
With telemetric pressure monitors implanted, women with active idiopathic intracranial hypertension received exenatide or placebo. Exenatide lowered intracranial pressure by 5.7 cmCSF at 2.5 hours (p = 0.048), 6.4 at 24 hours (p = 0.030) and 5.6 at 12 weeks (p = 0.058), with no serious safety signals.
Olanzapine-related weight gain
In a double-blind trial in adults with obesity taking olanzapine, weight changed by -0.5 kg (-0.6%) on exenatide against +2.6 kg (+2.8%) on placebo. The main side effects were gastrointestinal symptoms and headaches, with no meaningful change in mood or psychotic symptoms.
Peripheral nerve function in type 2 diabetes
People with type 2 diabetes on exenatide had normal motor-nerve excitability, while those on DPP-4 or SGLT2 inhibitors showed abnormalities; in 10 people followed prospectively, exenatide improved nerve excitability over three months independently of HbA1c. An observational study.
Acute pancreatitis on Byetta, one case
A patient developed acute pancreatitis, confirmed by CT and blood tests, from the eighth day of Byetta treatment. Exenatide was withdrawn and the symptoms resolved. A single case report.
Dosing Data
Exenatide is dosed by label. Byetta starts at 5 µg twice daily and rises to 10 µg after a month; the weekly forms used 2 mg. It is not interchangeable with other exenatide products and should not be combined with them.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the Byetta label and the trials above.
Contraindications & Cautions
From the Byetta label; a clinician decides.
Legal Status
Exenatide is an approved prescription medicine in the US. The sport row below comes from the dataset.
Frequently Asked Questions
?Is exenatide really from Gila monster venom?
Its label says it was originally identified in the lizard Heloderma suspectum, the Gila monster. The drug is a synthetic copy, a 39-amino-acid peptide made in a laboratory.
?Is exenatide still available in the US?
Drugs@FDA lists Bydureon, Bydureon BCise and Byetta's original application as discontinued, but a Byetta label is still posted on DailyMed and a generic exenatide injection was approved on November 19, 2024 (read September 28, 2026).
?How does exenatide compare with semaglutide?
In a 56-week head-to-head trial, weekly semaglutide lowered HbA1c by 1.5 points against 0.9 with weekly exenatide, and weight by 5.6 kg against 1.9 kg.
?Does exenatide help Parkinson's disease?
A 2017 phase 2 trial suggested it might, but the 2025 phase 3 trial in 194 people found no difference from placebo after 96 weeks (p = 0.47).
?Does exenatide protect the heart?
In EXSCEL it was safe for the heart but did not significantly reduce major cardiovascular events (11.4% vs 12.2%, hazard ratio 0.91).
References
- [fda-pi] Byetta (exenatide) injection Prescribing Information. AstraZeneca (DailyMed version of 2025-09-08, read 2026-09-28).
- [fda-pi] US FDA, Drugs@FDA: Byetta NDA 021773 (April 28, 2005), Bydureon NDA 022200 (January 27, 2012), Bydureon BCise NDA 209210 (October 20, 2017), all listed as discontinued; exenatide injection ANDA 206697 (Amneal, November 19, 2024) (read 2026-09-28).
- [Human] Holman RR, et al. "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes." N Engl J Med, 2017;377(13):1228-1239. PMID: 28910237.
- [Human] Ahmann AJ, et al. "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial." Diabetes Care, 2018;41(2):258-266. PMID: 29246950.
- [Human] Ruff CT, et al. "Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial." Nat Med, 2022;28(1):89-95. PMID: 34873344.
- [Human] Tamborlane WV, et al. "Once-Weekly Exenatide in Youth With Type 2 Diabetes." Diabetes Care, 2022;45(8):1833-1840. PMID: 35679098.
- [Human] Athauda D, et al. "Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial." Lancet, 2017;390(10103):1664-1675. PMID: 28781108.
- [Human] Vijiaratnam N, et al. "Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial." Lancet, 2025;405(10479):627-636. PMID: 39919773.
- [Human] Mullins RJ, et al. "A Pilot Study of Exenatide Actions in Alzheimer's Disease." Curr Alzheimer Res, 2019;16(8):741-752. PMID: 31518224.
- [Human] Mitchell JL, et al. "The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial." Brain, 2023;146(5):1821-1830. PMID: 36907221.
- [Human] Patino LR, et al. "A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults." J Affect Disord, 2025;382:116-122. PMID: 40203970.
- [Human] Issar T, et al. "Effect of exenatide on peripheral nerve excitability in type 2 diabetes." Clin Neurophysiol, 2021;132(10):2532-2539. PMID: 34455311.
- [Human] Tripathy NR, et al. "Exenatide and acute pancreatitis." J Assoc Physicians India, 2008;56:987-8. PMID: 19322980.
Sources & Citations
Every PubMed citation on this page has been checked against its record. The Byetta label was read on DailyMed and approval records on Drugs@FDA on September 28, 2026. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.